Veronique Litalien

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

MNT: a new target for AML.

MNT: a new target for AML.

Journal: Blood neoplasia
Published: January 14, 2025

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.

Journal: Cancer cell
Published: July 23, 2023

STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.

STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.

Journal: Blood
Published: May 16, 2022

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.

Journal: Blood
Published: March 14, 2022

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death.

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death.

Journal: Cancer discovery
Published: April 24, 2021

Author Correction: Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.

Author Correction: Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.

Journal: Nature communications
Published: February 20, 2021

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

Journal: Blood
Published: November 29, 2020

Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.

Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.

Journal: Cancer discovery
Published: August 10, 2020

Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.

Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.

Journal: Blood advances
Published: December 30, 2019

Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.

Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.

Journal: Nature communications
Published: June 18, 2019

High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.

High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.

Journal: The Journal of clinical investigation
Published: January 13, 2016
Showing 1-11 of 11

Last Updated: 09/26/2026